cu(ii)gtsm

Cu(II)GTSM is a cell-permeable copper complex of glyoxal bis(N4-methylthiosemicarbazone). It acts as a potent inhibitor of glycogen synthase kinase 3 beta (GSK3β), reducing tau phosphorylation and suppressing neurotoxic amyloid β oligomers and trimers. In preclinical models of Alzheimer's disease, it has been shown to restore cognitive performance by reducing amyloid pathology and tau phosphorylation. Mechanistically, Cu(II)GTSM increases intracellular copper levels via reduction inside cells; this bioavailable copper pool induces oxidative stress selectively in cancer cells. The compound also modulates P-glycoprotein expression at the blood-brain barrier and demonstrates anticancer activity in prostate cancer models as well as antimicrobial effects against clinical isolates[1][3][5][6]. Its primary use is experimental; it is not approved for human or veterinary therapeutic use.

Other names

(SP-4-2)-[[2,2′-(1,2-ethanediylidene)bis[N-methylhydrazinecarbothioamidato-κN2,κS]](2-)]-copperglyoxalbis(N4-methylthiosemicarbazonato)copper(II)CAS 68341-14-0CAS68341-14-0CAS-68341-14-0